Navigation Links
Micromet Closes $80.5 Million Public Offering of Common Stock
Date:8/4/2009

logy. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, eff
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
2. Micromet Announces Pricing of Public Offering of Common Stock
3. Micromet Announces Public Offering of Common Stock
4. Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
5. Micromet Added to Russell 3000 Index
6. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
7. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
8. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
9. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
10. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
11. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China ... the "Company"), a leading fully integrated plasma-based biopharmaceutical ... announced that its majority-owned subsidiary, Shandong Taibang Biological ... ("GMP") certification from the China Food and Drug ... production facility. As previously disclosed in the Company,s ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... -- GenomeDx Biosciences today announced that a new study ... test for prostate cancer, was able to predict rapid ... prostatectomy without adjuvant therapy. Although rapid metastasis in men ... genomics to identify these men who have a highly ... The study has been published online by the ...
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Coulter, Inc. (NYSE: BEC ), a leading ... and innovate complex biomedical testing, announced today it will ... at 5:00 p.m. ET to discuss the company,s third ... call, there will be a webcast presentation of accompanying ...
... 13 Osteotech, Inc. (Nasdaq: OSTE ), ... for regenerative healing, announced today that it has received ... Commission granted early termination of the Hart-Scott-Rodino waiting period ... of the merger remains subject to antitrust clearance in ...
... 13, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:Beckman Coulter to host Conference Call and Webcast Presentation for Third Quarter 2010 Earnings Results on October 27, 2010 2Osteotech Announces Early Termination of HSR Waiting Period 2Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 2Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 3Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 4Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 5Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 6Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 7Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 8
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... water pathogens may get a lot easier and cheaper thanks ... his team. , Syed Hashsham, an associate professor in ... for Microbial Ecology, is developing a portable, hand-held device capable ... water and food. , "This device will give ...
... failure and other health conditions, blood draws and diagnostic tests ... chemical or physiologic changes silently cause damage that is not ... future a tiny device, one the size of a nickel ... monitor and detect abnormalities, and could then relay data to ...
... the thymus, where the immune system's T cells develop, if ... thousands of proteins as "self." The research confirms an ... the immune system, and not only at the sites where ... of type 1 diabetes, or the joints in rheumatoid arthritis. ...
Cached Biology News:Professors to develop hand-held pathogen testing device 2Cardiologist's 'living chip' changes science of disease monitoring 2Cardiologist's 'living chip' changes science of disease monitoring 3Cardiologist's 'living chip' changes science of disease monitoring 4Proteins anchor memories in our brain 2Proteins anchor memories in our brain 3
... 9001:2000 Certified USDA Research Registered OLAW Assured ... Training AALAS Certified Technicians Documentation ... Documentation Upon Request Focus CRP ... all your custom immunology service needs. ...
Request Info...
... IHC Protocol Development ,Antibody Titer and ... Animal or Human Cells and Tissues ... Tissues ,Peroxidase, Alkaline Phosphatase, Immunogold, and ... Microscopy ,Protein Localization in Transgenic Animals ...
Request Info...
Biology Products: